New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:52 EDTORAN, SLB, SNYWestern companies may seek return to Iran as sanctions ease, WSJ says
Temporary sanctions relief hasn't yet translated into an economic turnaround in Iran, but a steady flow of executives in recent weeks signals that some companies that previously did business there, such as Schlumberger (SLB), Sanofi (SNY), and Orange (ORAN), may be interested in exploring a return, according to The Wall Street Journal. Reference Link
News For ORAN;SNY;SLB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2015
14:20 EDTSNYFDA approves Regeneron, Sanofi cholesterol-lowering treatment
The announced the approval of Praluent injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 inhibitors. Praluent is approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol. Praluent is marketed by Sanofi-Aventis (SNY) and Regeneron (REGN). Shares of Regeneron remain halted.
07:21 EDTSNYRegeneron, Sanofi say CHMP recommends Euro approval of Praluent treatment
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the European Medicine Agency's Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion for the marketing authorization of Praluent, recommending its approval for use in certain adult patients with hypercholesterolemia. Praluent is an investigational fully human monoclonal antibody targeting PCSK9. The European Commission is expected to make a final decision on the Marketing Authorization Application for Praluent in the European Union in late September. The CHMP opinion was based on the benefit-risk profile of Praluent, following review of efficacy and safety data from more than 5,000 patients across 10 pivotal Phase 3 double-blind trials ranging from six months to two years. Clinical data from the ODYSSEY Phase 3 program show consistent, positive results in reducing LDL-C. The U.S. Food and Drug Administration has set a target action date of July 24 for the Biologics License Application of Praluent. The safety and efficacy of Praluent have not been fully evaluated by any other regulatory authority.
07:18 EDTSNYRegeneron and Sanofi's Praluent recommended for approval in Europe
Regeneron (REGN) and Sanofi (SNY) announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Praluent, recommending its approval for use in certain adult patients with hypercholesterolemia. Praluent is an investigational fully human monoclonal antibody targeting PCSK9. The European Commission is expected to make a final decision on the Marketing Authorization Application for Praluent in the European Union in late September.
07:16 EDTSNYFDA PDUFA Date for Regeneron and Sanofi BLA for Praluent is July 24, 2015
Subscribe for More Information
July 22, 2015
06:39 EDTSLBEuro, U.S. oil and gas groups to find tough competition in Iran, WSJ says
European and U.S. oil and gas firms drawn to Iran as sanctions lessen can expect not only opportunities, but also Iranian companies offering tough competition or joint ventures, the Wall Street Journal reports. Though no Iran-based companies have the clout of firms such as Exxon Mobil (XOM) or Schlumberger (SLB), companies that can take on engineering tasks are emerging and growing in Iran, the report says. If the Iran nuclear agreement comes into effect and sanctions are lifted against Iran sometime soon, those Iranian companies will be well positioned to compete for tens of billions of dollars worth of service contracts, the report adds. Other publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link
July 21, 2015
20:08 EDTORANSky criticizes 'highly damaging' proposal to merge BT Group, EE
Subscribe for More Information
12:47 EDTSNYPiper confident in Regeneron approval by Friday
After Amgen's (AMGN) Repatha received marketing authorization in Europe, making it the first of the anti-PCSK9 antibody to be approved worldwide, Piper Jaffray analyst Edward Tenthoff expressed confidence that Regeneron (REGN) and Sanofi's (SNY) anti-PCSK9 antibody Praluent will be approved by Friday's FDA action date. Tenthoff believes Praluent will eventually be a blockbuster drug, but anticipates the launch to be slow. He keeps a Neutral rating on Regeneron with a $484 price target.
12:09 EDTSLBSchlumberger upgraded to Buy from Hold at Societe Generale
Subscribe for More Information
10:01 EDTORANOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:38 EDTORANOrange SA downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded Orange SA to Hold citing limited upside to its price target following the stock's 72% rally since January 2014. Deutsche, however, believes there could be 16% upside should mobile consolidation succeed in France. It keeps an EU16.20 price target for shares.
July 20, 2015
17:49 EDTORANOrange to explore possible acquisition of Bharti Airtel subsidiaries
Orange and Bharti Airtel announced they have entered into an exclusive agreement to explore the possible acquisition by Orange of Airtelís subsidiaries in Burkina Faso, Chad, Congo Brazzaville and Sierra Leone. Reference Link
11:12 EDTSLBSchlumberger downgraded to Neutral from Buy at Tigress Financial
Subscribe for More Information
10:00 EDTSLBOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:31 EDTSLBSchlumberger upgraded to Buy from Neutral at Global Hunter
Subscribe for More Information
08:00 EDTSLBSchlumberger outlook remains favorable, says Oppenheimer
Subscribe for More Information
06:50 EDTSLBSchlumberger upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information
July 17, 2015
10:00 EDTSLBSchlumberger CEO says Halliburton deal creating 'uncertainty' for customers
Subscribe for More Information
09:53 EDTSLBSchlumberger says Q3 could 'potentially represent bottom' for revenue
Schlumberger management said on the company's Q2 earnings call that in North America in Q3 they expect a slight increase in activity on land, but they see this being offset by weakening offshore activity and further pricing pressure, both on land and offshore. Internationally, they see no "major change" in Q3 and they thinks the "overall weak activity" is going to continue, adding that they expect sustained pricing pressure. At this stage, the company's cost structure and field capacity is "really tailored" to its Q2 activity level, but, for now, they have decided to preserve the current structure for Q3 in order to be ready for increased activity going forward, the company added. Management said, "We are prepared to live with the temporary margin impact that carrying these slightly elevated levels of resources is going to have. It's not going to be a huge impact on margins but it's going to be a little bit more than what we could have managed if we were to cut even deeper."
09:47 EDTSLBSchlumberger says Q3 EPS consensus of 77c 'pretty realistic'
Subscribe for More Information
09:35 EDTSLBActive equity options trading on open
Active equity options trading on open: AAPL NFLX TSLA GOOG FB GOOGL SLB
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use